Google this: nephrologists-continue-to-report-high-omontys-awareness-usage-remains-low
This is from 5 weeks ago. Article says " "However, there is a high opportunity for Omontys to increase patient share as evidenced by the fact that surveyed nephrologists believe that over half of their hemodialysis ESA-treated patients are likely Omontys candidates."
Over half are likely Omontys candidates! Half would be great! There are 410,000 dialysis patients in the US alone.
I wonder how good the 5 weeks have been since this report came out? My feeling is, pretty good. Share price has dropped significantly in the last week or two but so has the share price of all small biotech. The previous high flying stuff is probably a better indicator of how well Omontys is being received.